Pharmacoproteomics and the Microbiome

New Horizons in Personalized Therapeutics
Erscheinungsjahr 2026
ISBN: 978-3-032-35563-8
Verlag: Springer

Buch, Englisch, Format (B × H): 155 mm x 235 mm

This book offers a comprehensive overview of the rapidly evolving fields of pharmacoproteomics and microbiome science, and their synergistic role in shaping the future of precision medicine. Written by leading experts, it explores how proteomic profiles and microbial communities interact to influence drug metabolism, therapeutic efficacy, and disease progression. The first section explains the principles of pharmacoproteomics and microbiome biology, followed by detailed discussions on molecular interactions and crosstalk between host proteins and microbial ecosystems. Subsequent sections delve into cutting-edge analytical platforms, including mass spectrometry-based proteomics, metaproteomics, and AI-driven multi-omics integration, highlighting their application in biomarker discovery and drug response prediction. The clinical chapters provide disease-specific insights into how these interactions impact neurological disorders, autoimmune conditions, infectious diseases, oncology, and cardiometabolic health. The book is rounded out with a discussion of ethical and regulatory considerations, translational challenges, and future directions for the next generation of personalized therapeutics.

Zielgruppe

Research

Autoren/Hrsg.

Anitha, Kuttiappan

Mishra, Neeraj

Ashique, Sumel

Fachgebiete

• Naturwissenschaften Biowissenschaften Mikrobiologie
• Naturwissenschaften Biowissenschaften Biochemie (nichtmedizinisch)
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie

Inhaltsverzeichnis

Introduction to Pharmacoproteomics and the Microbiome.- The Human Microbiome: Composition and Function.- Pharmacoproteomics: Bridging Proteins and Drug Responses.- Microbiome and Proteome Crosstalk in Disease.- Association between Pharmacoproteomics and the Microbiome.- Microbiome Engineering for Therapeutic Innovation.- Microbiome Analytics and Metaproteomics.- Data Integration, Machine Learning, and AI.- Pharmacoproteomics and Microbiome in Neurological and Neuropsychiatric Disorders.- Pharmacoproteomics and Microbiome in Autoimmune Disorders.- Pharmacoproteomics and Microbiome in Infectious Disorders.- Pharmacoproteomics and Microbiome in Oncology.- Pharmacoproteomics and Microbiome in Inflammatory Bowel Disorders.- Pharmacoproteomics and Microbiome in Cardiometabolic Diseases.- Ethical and Regulatory Challenges in Personalized Medicine.- Future Directions: Transforming Healthcare with Pharmacoproteomics and the Microbiome.

Über Autor(innen)

Dr. Kuttiappan Anitha is Assistant Professor at the School of Pharmacy and Technology Management, Shri Vile Parle Kelavani Mandal Narsee Monjee Institute of Management Studies, Deemed to be University, Shirpur, with 14 years of teaching and research experience. She has received awards including the “Excellence in Academic Award” and “Pratibha – Eaton Excellence Award” from the Government of Andhra Pradesh. Her expertise includes immuno-oncology, gut microbiota, and infectious diseases.

Dr. Neeraj Mishra is Professor and Head of Pharmaceutics at Amity Institute of Pharmacy, Gwalior, with 20 years of teaching and research experience.  He has more than 100 publications of International and National repute in recent concepts of novel drug delivery systems, localized drug delivery, targeted and controlled drug delivery of nanocarriers/ microparticles for the treatment of breast, colon cancer, and neurodegenerative disorders. 

Sumel Ashique is Assistant Professor in Department of Pharmaceutical Technology, School of Health and Medical Sciences, Adamas University, Kolkata, West Bengal, India  with expertise in drug delivery, nanotechnology, and microbiome research. He has published over 80 papers and 20 book chapters and holds five patents. Currently pursuing his Ph.D., he has contributed significantly to targeted treatment strategies and personalized therapeutics.